Euclidean Capital

Founded 2009

Overview

Unlock datapoints

Portfolio analytics

Team

Investments

News & Media

Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.
Total investments 18
Average round size
info
The average size of a deal this fund participated in
$82M
Portfolio companies 15
Rounds per year 1.50
Lead investments 1
Follow on index
info
How often the fund supports its portfolio startups at next rounds
0.28
Exits 2
Key employees 2

Areas of investment

  • Biotechnology
  • Health Care
  • Medical Device
  • Machine Learning
  • Medical
Summary

The common things for fund are deals in the range of 50 - 100 millions dollars. The fund is generally included in 2-6 deals every year. Comparing to the other companies, this Euclidean Capital performs on 16 percentage points less the average number of lead investments. The high activity for fund was in 2019. When the investment is from Euclidean Capital the average startup value is more than 1 billion dollars. The top amount of exits for fund were in 2019. Considering the real fund results, this VC is 5 percentage points more often commits exit comparing to other organizations.

The typical case for the fund is to invest in rounds with 7-8 participants. Despite the Euclidean Capital, startups are often financed by Polaris Partners, OrbiMed, GV. The meaningful sponsors for the fund in investment in the same round are Topspin Partners, The Column Group, Polaris Partners. In the next rounds fund is usually obtained by Viking Global Investors, Two Sigma Ventures, Topspin Partners.

The fund has specific favorite in a number of founders of portfolio startups. When startup sums 4 or 5+ of the founder, the probability for it to get the investment is little. Among the most successful fund investment fields, there are Biotechnology, SaaS. Among the most popular portfolio startups of the fund, we may highlight 23andMe, Alector, ArsenalBio. Moreover, a startup needs to be at the age of 6-10 years to get the investment from the fund.

Besides them, we counted 2 critical employees of this fund in our database.

Read more

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

Circle Pharma

Biotechnology
Clinical Trials
Health Care
Therapeutics
$66M16 Jun 2021 San Francisco, California, United States

ASAPP

Artificial Intelligence
CRM
Customer Service
Enterprise Software
Machine Learning
Sales Automation
Software
$120M19 May 2021 New York, New York, United States

SetPoint Medical

Biotechnology
Health Care
Medical Device
Neuroscience
$64M27 Jan 2021 Santa Clarita, California, United States

A2 Biotherapeutics

Biotechnology
Life Science
$71M06 Oct 2020 California, United States

Health Care
Medical
Wellness
$73M29 Jul 2020 South San Francisco, California, United States

ASAPP

Artificial Intelligence
CRM
Customer Service
Enterprise Software
Machine Learning
Sales Automation
Software
$185M01 May 2020 New York, New York, United States

Dascena

Health Care
Machine Learning
Medical Device
$50M30 Apr 2020 Oakland, California, United States

Kallyope

Biotechnology
Health Care
Medical
Pharmaceutical
$112M05 Mar 2020 New York, New York, United States

Codagenix

Biotechnology
Genetics
$20M13 Jan 2020 New York, United States
News
Drone data analytics provider DroneBase nabs $20M

– DroneBase, a company providing drones as a service to capture high-resolution aerial photos, announced that it raised $20 million in a funding round led by Euclidean Capital with participation from Union Square Ventures, Upfront Ventures, Energy Transition Ventures, Hearst Ventures, Pritzker Group Venture Capital, and Valor Equity Partners.
– The company says that the funds will be put toward expansion in the renewable energy industry and other segments with “high-value” infrastructure, like commercial real estate and insurance.
– Investments in drone startups are growing as the benefits of AI applied to aerial photography become clear. For example, algorithms analyze images from drones to monitor for corrosion, pests, and even livestock health. And insurers like State Farm leverage drones for claims inspections, assessing on-the-ground damage, and emergency resources following a disaster.

Ribon Therapeutics Secures $65 Million Financing

– Ribon Therapeutics announced the closing of a $65m financing.
– The financing was led by Deerfield Management and U.S. Venture Partners, with support from new investors Avego BioScience Capital, GV (formerly Google Ventures), Monashee Investment Management and Peregrine Ventures, along with existing investors AbbVie Ventures, Bristol Myers Squibb, Euclidean Capital, Johnson & Johnson Innovation, Novartis Venture Fund, Osage University Partners, Takeda Ventures and The Column Group.
– Ribon will use the proceeds to support the clinical development of its novel precision medicine candidates.

Review

  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Euclidean Capital?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!

Wait!
You can raise money with us faster

Get matched with relevant funds

Find decision makers data

Connect with investors by email

Remind me later
...and save more than 200 hours*
*-Our recommendation and outreach system saves up to 200 hours of founder time on fundraising for seed and series A+ startups
We use LinkedIn only to verify your account. We don't import or message your contacts, nor post on your behalf.
By creating an account, you agree to our Terms of Service and Privacy Policy.
Crunchbase icon

Content report

The following text will be sent to our editors: